(ACRV) Acrivon Therapeutics - Performance -81.8% in 12m
ACRV performance: live returns, drawdowns, peer ranking & SPY comparison from 1w to 5y, all in one clean chart-driven dashboard.
Performance Rating
-64.46%
#92 in Peer-Group
Rel. Strength
2.71%
#7467 in Stock-Universe
Total Return 12m
-81.75%
#183 in Peer-Group
Total Return 5y
-92.25%
#126 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | - |
| P/E Forward | - |
| High / Low | USD |
|---|---|
| 52 Week High | 9.98 USD |
| 52 Week Low | 1.05 USD |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 75.83 |
| Buy/Sell Signal +-5 | -0.28 |
| Support / Resistance | Levels |
|---|---|
| Support | |
| Resistance |
12m Total Return: ACRV (-81.8%) vs XBI (-7%)
5y Drawdown (Underwater) Chart
Top Performer in Biotechnology
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| GILD NASDAQ Gilead Sciences |
3.23% | 73% | 77.8% | 22.7 | 13.6 | 0.23 | 28.3% | -3.71% |
| UTHR NASDAQ United Therapeutics |
-9.1% | -6.38% | 147% | 11.3 | 10.5 | 1.43 | 74.6% | 16.1% |
| AMGN NASDAQ Amgen |
3.91% | -0.97% | 36% | 25.4 | 13.4 | 0.93 | 0.60% | 41% |
| BIM PA Biomerieux |
1.34% | 27.6% | -4.82% | 33.1 | 25.8 | 1.55 | -38.5% | -25.1% |
| NBIX NASDAQ Neurocrine Biosciences |
3.69% | -7.17% | 1.14% | 43 | 24.8 | 0.27 | 18.7% | -34.3% |
| KMDA NASDAQ Kamada |
18.3% | 43% | -4.19% | 27.6 | 22.4 | 0.9 | 68.9% | 36.8% |
| PTCT NASDAQ PTC Therapeutics |
-4.03% | 58.7% | -9.25% | 7.71 | 6.26 | 0.81 | - | 68% |
| ERF PA Eurofins Scientific SE |
6.2% | 28.7% | 15.2% | 28.9 | 15.4 | 0.64 | -62.1% | -19.3% |
Performance Comparison: ACRV vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for ACRV
| Total Return (including Dividends) | ACRV | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 4.88% | 3.36% | 5.25% |
| 3 Months | -14.57% | 15.73% | 24.13% |
| 12 Months | -81.75% | -7.02% | 14.15% |
| 5 Years | -92.25% | -24.21% | 111.83% |
| Trend Score (consistency of price movement) | ACRV | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -7.5% | 4.4% | 81% |
| 3 Months | -56% | 78.8% | 96.9% |
| 12 Months | -90.9% | -85.8% | 44.9% |
| 5 Years | -74.3% | -52.6% | 84% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
|---|---|---|---|
| 1 Month | %th67.00 | 1.47% | -0.35% |
| 3 Month | %th16.50 | -26.18% | -31.18% |
| 12 Month | %th8.50 | -80.38% | -84.02% |
| 5 Years | %th29.50 | -92.39% | -95.25% |
FAQs
Does Acrivon Therapeutics (ACRV) outperform the market?
No,
over the last 12 months ACRV made -81.75%, while its related Sector, the SPDR S&P Biotech (XBI) made -7.02%.
Over the last 3 months ACRV made -14.57%, while XBI made 15.73%.
Performance Comparison ACRV vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
ACRV vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 5.8% | -0.4% | -86.7% | -96% |
| US NASDAQ 100 | QQQ | 6% | -0.4% | -87.3% | -94% |
| German DAX 40 | DAX | 7.9% | 6.3% | -98.8% | -111% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 6% | 1.6% | -90.1% | -102% |
| Hongkong Hang Seng | HSI | 6.2% | -1.2% | -106.1% | -120% |
| India NIFTY 50 | INDA | 7.6% | 1.4% | -87% | -81% |
| Brasil Bovespa | EWZ | 3.3% | -3.9% | -111.7% | -92% |
ACRV vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 7.2% | -1% | -90.8% | -106% |
| Consumer Discretionary | XLY | 6.3% | 1.7% | -79% | -100% |
| Consumer Staples | XLP | 5.5% | 4.2% | -88.3% | -91% |
| Energy | XLE | 5.5% | -2.2% | -82.6% | -82% |
| Financial | XLF | 5.1% | -0.2% | -91.6% | -112% |
| Health Care | XLV | 6.3% | 2.7% | -79.3% | -77% |
| Industrial | XLI | 5.7% | 0.7% | -94.5% | -107% |
| Materials | XLB | 3.5% | 0.6% | -91.2% | -88% |
| Real Estate | XLRE | 5.9% | 3.9% | -86.4% | -95% |
| Technology | XLK | 5% | -3.8% | -89% | -93% |
| Utilities | XLU | 6.9% | 3.1% | -89.9% | -105% |
| Aerospace & Defense | XAR | 7.9% | -2.2% | -105.2% | -131% |
| Biotech | XBI | 4.8% | 1.5% | -73.5% | -75% |
| Homebuilder | XHB | 3.3% | -2.1% | -79.5% | -87% |
| Retail | XRT | 3.3% | -0.1% | -82.4% | -93% |
ACRV vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | 4.9% | -3.56% | -78.3% | -74% |
| Natural Gas | UNG | 15.3% | 14.7% | -69.9% | -80% |
| Gold | GLD | 5.5% | 6.1% | -107.3% | -121% |
| Silver | SLV | 4.8% | -2% | -104% | -99% |
| Copper | CPER | 6.7% | 0.3% | -103.7% | -93% |
ACRV vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | 7.6% | 3.8% | -83.2% | -80% |
| iShares High Yield Corp. Bond | HYG | 7% | 3.3% | -85.6% | -92% |